Antineoplastic Combined Chemotherapy Protocols
"Antineoplastic Combined Chemotherapy Protocols" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
| Descriptor ID |
D000971
|
| MeSH Number(s) |
E02.183.750.500 E02.319.077.500 E02.319.310.037
|
| Concept/Terms |
Antineoplastic Combined Chemotherapy Protocols- Antineoplastic Combined Chemotherapy Protocols
- Combined Antineoplastic Agents
- Antineoplastic Agents, Combined
- Agent, Combined Antineoplastic
- Agents, Combined Antineoplastic
- Antineoplastic Agent, Combined
- Combined Antineoplastic Agent
- Antineoplastic Combined Chemotherapy Regimens
- Drug Combinations, Antineoplastic
- Anticancer Drug Combinations
- Anticancer Drug Combination
- Drug Combination, Anticancer
- Drug Combinations, Anticancer
- Antineoplastic Drug Combinations
- Antineoplastic Drug Combination
- Combinations, Antineoplastic Drug
- Drug Combination, Antineoplastic
Antineoplastic Chemotherapy Protocols- Antineoplastic Chemotherapy Protocols
- Antineoplastic Chemotherapy Protocol
- Chemotherapy Protocol, Antineoplastic
- Protocol, Antineoplastic Chemotherapy
- Protocols, Antineoplastic Chemotherapy
- Cancer Chemotherapy Protocols
- Cancer Chemotherapy Protocol
- Chemotherapy Protocol, Cancer
- Chemotherapy Protocols, Cancer
- Protocol, Cancer Chemotherapy
- Protocols, Cancer Chemotherapy
- Chemotherapy Protocols, Antineoplastic
|
Below are MeSH descriptors whose meaning is more general than "Antineoplastic Combined Chemotherapy Protocols".
Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Combined Chemotherapy Protocols".
This graph shows the total number of publications written about "Antineoplastic Combined Chemotherapy Protocols" by people in this website by year, and whether "Antineoplastic Combined Chemotherapy Protocols" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1996 | 0 | 1 | 1 |
| 1997 | 1 | 0 | 1 |
| 1998 | 1 | 0 | 1 |
| 1999 | 3 | 0 | 3 |
| 2000 | 1 | 1 | 2 |
| 2002 | 2 | 1 | 3 |
| 2003 | 2 | 1 | 3 |
| 2004 | 3 | 2 | 5 |
| 2005 | 5 | 2 | 7 |
| 2006 | 9 | 2 | 11 |
| 2007 | 7 | 1 | 8 |
| 2008 | 13 | 0 | 13 |
| 2009 | 9 | 3 | 12 |
| 2010 | 9 | 1 | 10 |
| 2011 | 13 | 5 | 18 |
| 2012 | 7 | 1 | 8 |
| 2013 | 10 | 1 | 11 |
| 2014 | 15 | 1 | 16 |
| 2015 | 15 | 4 | 19 |
| 2016 | 9 | 3 | 12 |
| 2017 | 14 | 5 | 19 |
| 2018 | 10 | 5 | 15 |
| 2019 | 20 | 4 | 24 |
| 2020 | 18 | 8 | 26 |
| 2021 | 13 | 8 | 21 |
| 2022 | 3 | 11 | 14 |
| 2023 | 1 | 2 | 3 |
| 2024 | 4 | 4 | 8 |
| 2025 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antineoplastic Combined Chemotherapy Protocols" by people in Profiles.
-
A phase 1 study of the combination of BH3-mimetic, navitoclax, and mTORC1/2 inhibitor, vistusertib, in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2025 Feb 25; 95(1):37.
-
Update on safety and feasibility of the combination of pembrolizumab and pelvic chemoradiation in locally advanced cervical cancer. Cancer. 2025 Feb 15; 131(4):e35757.
-
Dose finding, bioavailability, and PK-PD of oral triapine with concurrent chemoradiation for locally advanced cervical cancer and vaginal cancer (ETCTN 9892). Cancer Chemother Pharmacol. 2024 Dec 14; 95(1):4.
-
Outcomes of frail patients undergoing high-dose chemotherapy and autologous stem cell transplantation for multiple myeloma. Br J Haematol. 2024 Dec; 205(6):2370-2375.
-
Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT. Clin Cancer Res. 2024 Aug 01; 30(15):3167-3178.
-
Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel in the randomized ENGOT-EN6/GOG-3031/RUBY trial. Ann Oncol. 2024 Aug; 35(8):728-738.
-
Phase I and Randomized Phase II Study of Ruxolitinib With Frontline Neoadjuvant Therapy in Advanced Ovarian Cancer: An NRG Oncology Group Study. J Clin Oncol. 2024 Jul 20; 42(21):2537-2545.
-
Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors. Clin Cancer Res. 2024 May 01; 30(9):1739-1749.
-
The MUC1-HIF-1a signaling axis regulates pancreatic cancer pathogenesis through polyamine metabolism remodeling. Proc Natl Acad Sci U S A. 2024 Apr 02; 121(14):e2315509121.
-
Phase 1 trial of navitoclax and sorafenib in patients with relapsed or refractory solid tumors with hepatocellular carcinoma expansion cohort. Invest New Drugs. 2024 Feb; 42(1):127-135.